As of Thursday close, BioXcel Therapeutics Inc.’s (NASDAQ:BTAI) stock was up $1.09, moving up 11.27 percent to $10.76. The average number of shares traded per day over the past five days has been 860,660 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.95 fall in that time frame. In the last twenty days, the average volume was 681,425, while in the previous 50 days, it was 910,656.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, BTAI stock retreated -31.68%. Shares of the company fell to $9.08 on 05/12/22, the lowest level in the past month. A 52-week high of $39.00 was reached on 04/06/22 after having rallying from a 52-week low of $9.60. Since the beginning of this year, BTAI’s stock price has dropped by -47.07% or -$9.57, and marked a new high 4 times. However, the stock has declined by -72.41% since its 52-week high.
BioXcel Therapeutics Inc. (BTAI) last reported insider trading activity 322 days ago on Jun 25. Nandabalan Krishnan, the Director of the company, disposed of 473,250 shares for $30.83 on Jun 25. It resulted in a $14,589,493 divestment by the insider. Mehta Vimal sold 473,250 shares at an average price of $30.83 on Jun 25. The insider now owns 8,546,750 shares following the transaction. On Jun 25, 10% Owner BioXcel LLC sold 473,250 shares at $30.83 apiece. The transaction was valued at $14,589,493.
In the three months ended September 29, BioXcel Therapeutics Inc.’s quick ratio stood at 14.20, while its current ratio was 14.20, showing that the company is able to pay off its debt. Based on annual data, BTAI earned $40000.0 in gross profit and brought in $106.94 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected BioXcel Therapeutics Inc. to report -$1.05 quarterly earnings, the actual figure was -$0.96 per share, beating the consensus estimate by 8.60%. During the quarter, the company generated -$31.4 million in EBITDA. The liabilities of BioXcel Therapeutics Inc. were 17.02 million at the end of its most recent quarter ended September 29, and its total debt was $1.47 million. The value of shareholders’ equity is $27.98 million.
This quick technical analysis looks at BioXcel Therapeutics Inc.’s (BTAI) price momentum. With a historical volatility rate of 128.69%, the RSI 9-day stood at 32.35% on 12 May.
With respect to its five-day moving average, the current BioXcel Therapeutics Inc. price is down by -21.52% percent or -$2.95. At present, BTAI shares trade -33.25% below its 20-day simple moving average and -51.75% percent below its 100-day simple moving average. However, the stock is currently trading approximately -39.21% below its SMA50 and -59.76% below its SMA200.
Stochastic coefficient K was 14.32% and Stochastic coefficient D was 8.77%, while ATR was 1.47. Given the Stochastic reading of 29.07% for the 14-day period, the RSI (14) reading has been calculated as 33.58%. As of today, the MACD Oscillator reading stands at -1.89, while the 14-day reading stands at -2.31.
BofA Securities reiterated its a Buy rating on BioXcel Therapeutics Inc. (NASDAQ: BTAI) in a note to investors. The analysts firm has however raised their price target to $80, representing a possible 86.55% increase in the stock price.